Clinical Trial

Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this study is to learn if Ketamine works more efficiently, as compared to Opioids, for Sickle Cell Pain The main questions it aims to answer are: Does Ketamine lower the number of times participants need to be admitted for continued pain control during a Sickle Cell Pain Crisis. Does Ketamine decrease the amount of time it takes to reach adequate pain control/pain score improvement, as compared to Opioids. Patients could have too low or too high blood pressure or sleepiness. Researchers will compare Ketamine to Opioids (Morphine or Dilaudid) to see if Ketamine works to treat pain enough that you do not need to be admitted to the hospital. Participants will: On arrival to the Children's ER for Sickle Cell Pain crisis will get Ketamine, instead of Morphine or Dilaudid, along with the typical Tylenol, Toradol, Lidocaine patch for pain control while in the ER. During this time we will follow your reported pain scale (0-10) to monitor your pain response to the Ketamine, as well as follow rate of hospital admission.
Trial Details
NCT Number NCT07682662
Lead Sponsor University of Mississippi Medical Center
Conditions Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD)
Enrollment 400 participants
Start Date 2026-08-01
Primary Completion 2029-08-31 (estimated)
Study Completion 2029-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-06